Peter Loftus is a reporter for The Wall Street Journal in Philadelphia covering the pharmaceutical and medical-device ...

Shares of Becton Dickinson & Co. BDX advanced 1.05% to $204.45 Thursday, on what proved to be an all-around positive trading ...

The US Court of Appeals for the Federal Circuit affirmed a Patent Trial & Appeal Board unpatentability determination, finding that a skilled ...

BP is not Elliott’s only current campaign in the oil fields. In the spring of 2024, Elliott revealed a $1 billion stake in ...

Becton, Dickinson and Company (BD) has received the US Food and Drug Administration’s (FDA) 510(k) clearance for the Phasix ...

Detailed price information for Intuitive Surg Inc (ISRG-Q) from The Globe and Mail including charting and trades.

Government contractors lose billions annually on contracts they should have won due to one simple, fixable mistake, writes BD ...

Shares of Becton Dickinson & Co. BDX rose 1.22% to $202.32 Wednesday, on what proved to be an all-around favorable trading ...

Traders have long known Donald Trump intended to use tariffs as a tool for economic policy. Citigroup Inc., a year ago, even ...

Piper Sandler analyst Jason Bednar lowered the firm’s price target on Becton Dickinson to $260 from $280 and keeps an Overweight rating on the ...

BD (NYSE: BDX) announced today that it received FDA 510(k) clearance for its Phasix ST umbilical hernia patch.

Piper Sandler analyst Jason Bednar maintained a Buy rating on Becton Dickinson (BDX – Research Report) today and set a price target of $260.00.